With 5.77 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.38 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $50.87 whereas the lowest price it dropped to was $46.49. The 52-week range on GRAL shows that it touched its highest point at $63.99 and its lowest point at $12.33 during that stretch. It currently has a 1-year price target of $40.50. Beta for the stock currently stands at 3.54.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GRAL was up-trending over the past week, with a rise of 6.05%, but this was up by 17.77% over a month. Three-month performance surged to 69.31% while six-month performance rose 158.49%. The stock gained 171.09% in the past year, while it has gained 184.65% so far this year. A look at the trailing 12-month EPS for GRAL yields -60.80 with Next year EPS estimates of -13.48. For the next quarter, that number is -3.57. This implies an EPS growth rate of 78.36% for this year and 1.96% for next year. EPS is expected to grow by 42.76% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -89.93%.
Float and Shares Shorts:
At present, 35.30 million GRAL shares are outstanding with a float of 29.79 million shares on hand for trading. On 2025-06-13, short shares totaled 5.96 million, which was 1655.9999999999998 higher than short shares on 1747267200. In addition to Mr. Robert P. Ragusa as the firm’s CEO & Director, Dr. Joshua J. Ofman M.D., M.S.H.S serves as its President.
Institutional Ownership:
Through their ownership of 0.66344 of GRAL’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, GRAL reported revenue of $31837000.0 and operating income of -$153607000.0. The EBITDA in the recently reported quarter was -$114328000.0 and diluted EPS was -$3.1.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With GRAL analysts setting a high price target of 43.0 and a low target of 38.0, the average target price over the next 12 months is 40.5. Based on these targets, GRAL could drop -11.14% to reach the target high and fall by -21.47% to reach the target low. Reaching the average price target will result in a decline of -16.31% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$49.1248 being high and -$53.03454 being low. For GRAL, this leads to a yearly average estimate of -$51.26333.
